Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint

Ping Ren; Ming Luo; Shao Lin; Mahmoud A Ghannoum; Nancy Isham; Dan J Diekema; Michael A Pfaller; Shawn Messer; Shawn R Lockhart; Naureen Iqbal; Vishnu Chaturvedi

doi:10.1128/AAC.04545-14

Back

Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint

Journal article

Open access

Peer reviewed

Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint

Ping Ren, Ming Luo, Shao Lin, Mahmoud A Ghannoum, Nancy Isham, Dan J Diekema, Michael A Pfaller, Shawn Messer, Shawn R Lockhart, Naureen Iqbal, …

Antimicrobial agents and chemotherapy, Vol.59(3), pp.1759-1766

03/2015

DOI: 10.1128/AAC.04545-14

PMCID: PMC4325810

PMID: 25512402

Files and links (1)

url

https://doi.org/10.1128/AAC.04545-14View

Published (Version of record) Open Access

Abstract

Four laboratories tested three isolates of Candida species and two isolates of Aspergillus fumigatus using 96-well plates containing combinations of amphotericin B, anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole. The majority of summation fractional inhibitory concentration indices (ΣFICI) based on the Lowe additivity formula suggested indifferent drug interactions (ΣFICI > 0.5 and ≤4.0) and no instance of drug antagonism (ΣFICI > 4.0). The intra- and interlaboratory agreement rates were superior when MIC100 readings were used as endpoints (at a 99% confidence interval [CI]).

Antifungal Agents - pharmacology

Aspergillus fumigatus - drug effects

Candida - drug effects

Microbial Sensitivity Tests - methods

Drug Combinations

Details

Title: Subtitle: Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint
Creators: Ping Ren - Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA ping.ren@health.ny.gov
Ming Luo - Bureau of Environmental & Occupational Epidemiology, New York State Department of Health, Albany, New York, USA
Shao Lin - Bureau of Environmental & Occupational Epidemiology, New York State Department of Health, Albany, New York, USA
Mahmoud A Ghannoum - Center for Medical Mycology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, USA
Nancy Isham - Center for Medical Mycology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, USA
Dan J Diekema - Medical Microbiology Division, Department of Pathology, University of Iowa, Iowa City, Iowa, USA
Michael A Pfaller - Medical Microbiology Division, Department of Pathology, University of Iowa, Iowa City, Iowa, USA
Shawn Messer - Medical Microbiology Division, Department of Pathology, University of Iowa, Iowa City, Iowa, USA
Shawn R Lockhart - Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Naureen Iqbal - Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Vishnu Chaturvedi - Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.59(3), pp.1759-1766
Publisher: United States
DOI: 10.1128/AAC.04545-14
PMID: 25512402
PMCID: PMC4325810
ISSN: 1098-6596
eISSN: 1098-6596
Language: English
Date published: 03/2015
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986374402771

Metrics

16 Record Views

7 Times Cited - Web of Science